170 related articles for article (PubMed ID: 9072541)
1. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers--investigation by temperature gradient gel electrophoresis (TGGE).
Schlechte HH; Schnorr D; Löning T; Rudolph BD; Pohrt UM; Loening SA
J Urol; 1997 Mar; 157(3):1049-53. PubMed ID: 9072541
[TBL] [Abstract][Full Text] [Related]
2. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
[TBL] [Abstract][Full Text] [Related]
3. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
4. Selective detection of inactivating mutations of the tumor suppressor gene p53 in bladder tumors.
Pfister C; Flaman JM; Martin C; Grise P; Frebourg T
J Urol; 1999 Jun; 161(6):1973-5. PubMed ID: 10332483
[TBL] [Abstract][Full Text] [Related]
5. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
[TBL] [Abstract][Full Text] [Related]
6. Detection of p53 point mutations in primary human vulvar cancer by PCR and temperature gradient gel electrophoresis.
Sliutz G; Schmidt W; Tempfer C; Speiser P; Gitsch G; Eder S; Schneeberger C; Kainz C; Zeillinger R
Gynecol Oncol; 1997 Jan; 64(1):93-8. PubMed ID: 8995554
[TBL] [Abstract][Full Text] [Related]
7. p53 is mutated in a subset of advanced-stage prostate cancers.
Bookstein R; MacGrogan D; Hilsenbeck SG; Sharkey F; Allred DC
Cancer Res; 1993 Jul; 53(14):3369-73. PubMed ID: 8324747
[TBL] [Abstract][Full Text] [Related]
8. TP53 gene mutations in prostate cancer progression.
Ecke TH; Schlechte HH; Schiemenz K; Sachs MD; Lenk SV; Rudolph BD; Loening SA
Anticancer Res; 2010 May; 30(5):1579-86. PubMed ID: 20592345
[TBL] [Abstract][Full Text] [Related]
9. p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.
Schlechte H; Lenk SV; Löning T; Schnorr D; Rudolph BD; Ditscherlein G; Loening SA
Eur Urol; 1998; 34(5):433-40. PubMed ID: 9803007
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis.
Curigliano G; Ferretti G; Flamini G; Goldhirsch A; de Braud F; Calabro MG; Mandaly M; Nole F; De Pas T; D'Addessi A; Cittadini A
Anticancer Res; 2001; 21(4B):3015-20. PubMed ID: 11712804
[TBL] [Abstract][Full Text] [Related]
11. [p53 in urogenital tumors:analysis of expression and mutation].
Löning T; Schlechte H; Friedrichs K; Schnoor D; Ditscherlein G; Bommer G; Löning S
Verh Dtsch Ges Pathol; 1993; 77():117-8. PubMed ID: 7511267
[TBL] [Abstract][Full Text] [Related]
12. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
13. Analyses of p53 gene mutations in primary human bladder cancer.
Miyamoto H; Kubota Y; Shuin T; Torigoe S; Hosaka M; Iwasaki Y; Danenberg K; Danenberg PV
Oncol Res; 1993; 5(6-7):245-9. PubMed ID: 8123944
[TBL] [Abstract][Full Text] [Related]
14. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
15. Comparative assessment of the functional p53 status in glioma cells.
Kim EL; Yoshizato K; Kluwe L; Meissner H; Warnecke G; Zapf S; Westphal M; Deppert W; Giese A
Anticancer Res; 2005; 25(1A):213-24. PubMed ID: 15816541
[TBL] [Abstract][Full Text] [Related]
16. TP53 gene in blood plasma DNA of tumor patients.
Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G
Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941
[TBL] [Abstract][Full Text] [Related]
17. [The study of p53 gene mutation in human bladder cancer].
Ding Q; Zhang Y; Sun X
Zhonghua Wai Ke Za Zhi; 1995 Nov; 33(11):684-6. PubMed ID: 8731915
[TBL] [Abstract][Full Text] [Related]
18. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.
Isaacs WB; Carter BS; Ewing CM
Cancer Res; 1991 Sep; 51(17):4716-20. PubMed ID: 1873816
[TBL] [Abstract][Full Text] [Related]
19. Detection of loss of heterozygosity in the p53 tumor-suppressor gene with PCR in the urine of patients with bladder cancer.
Friedrich MG; Erbersdobler A; Schwaibold H; Conrad S; Huland E; Huland H
J Urol; 2000 Mar; 163(3):1039-42. PubMed ID: 10688045
[TBL] [Abstract][Full Text] [Related]
20. TP53 gene mutations as an independent marker for urinary bladder cancer progression.
Ecke TH; Sachs MD; Lenk SV; Loening SA; Schlechte HH
Int J Mol Med; 2008 May; 21(5):655-61. PubMed ID: 18425359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
